Dr Reddy's bets big on biosimilars, eyes regulated markets Economic Times At present, DRL's biosimilars portfolio includes filgrastim, peg-filgrastim, rituximab and darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. "Additionally, filings in 20 new countries await approval, and progress ... |
